All News

Because I am a lifelong learner and an educator at heart, I always feel the compelling need to share in case someone else out there might benefit from the fires I've walked through.

Michael J. Mauro, M.D., discusses advances in treating myeloproliferative disorders.

Patients' levels of health literacy often correlate to their understanding of clinical trial randomization, which has an effect on enrollment.

A Keytruda was recently granted a priority review to a supplemental biologics license application to treat patients with metastatic or advanced non-small cell lung cancer.

Although now in remission, Ed has agreed with the oncologist, to take two more rounds of chemo in hopes he might not have another relapse.

Accepting feelings of guilt is not only normal, but it's a part of life.

An article recently published in a special issue of CURE focused on lung cancer, “Quitting Smoking Is Possible and Reduces Cancer Risk,” has generated discussion on social media and in our Discussion Forum.

New advancements are quickly advancing the treatment landscape of lung cancer.

Tecentriq (atezolizumab) is being reviewed for the use in additional settings to treat bladder cancer.

In the past 30 years or so, there has been a transition in this country for those diagnosed with cancer. Not very long ago, a diagnosis of cancer meant being admitted to the hospital to wait out the final days in a haze of morphine.

Dimosthenis Andreou, M.D., discussed the Euro-EWING99 trial with CURE.

Many patients with cancer do not qualify for clinical trials because of comorbidities or other health problems. However, a recent study found that many of these patients can actually benefit from trials.

Patients with metastatic colorectal cancer now have more treatment options than ever, explains Tanios Bekaii-Saab, M.D.

Breast cancer and melanoma survivor shares coping tools that help her.

Fatigue affects many people, but cancer related fatigue is a very different malady.

A simple blood test may be able to notify patients and their health care providers if their oropharyngeal cancer is recurring.

Xofigo's role in the treatment of metastatic castration-resistant prostate cancer will continue to change.

CURE spoke with Carly O’Brien about some of the best tips and resources to deal with some of the challenges of head and neck cancer.

The clinical hold on pacritinib was recently lifted by the US Food and Drug Administration (FDA).

When zoledronic acid use happens less frequently, patients with breast cancer, prostate cancer or multiple myeloma with bone metastases did not see an increase in skeletal-related events.

Some quick lessons I’ve learned from a desert tortoise.

Sibylle Loibl, M.D., Ph.D., discusses the GeparSepto trial and what it means for women with breast cancer.

An early stage trial found that a new drug combination can reduce the rates of treatment-related diarrhea in patients with breast cancer.

Finding new biomarkers should be the top priority in ovarian cancer research, Maurie Markman, M.D., says.

When cancer strikes, we all have weapons at hand with which to fight.

Why my sudden interest in C. diff? Well, it doesn’t take a rocket engineer (which I am) to figure out that I caught a bad case.

Immunotherapy agents are drastically changing the treatment landscape – and outcomes – of patients with head and neck cancers.

Andrew D. Zelenetz, M.D., Ph.D. weighs in on recent research and the future of treating hematologic malignancies.